Navigation Links
Circassia Raises GBP11 Million ($21.8 Million) in Oversubscribed Second Round Funding
Date:1/29/2008

OXFORD, England, January 29 /PRNewswire/ -- Circassia Ltd, a specialty biopharmaceutical company focused on controlling immune system responses, announced today that it has successfully raised GBP11 million ($21.8 million) in an oversubscribed second round funding. The investment syndicate includes new investors Goldman Sachs and Invesco Perpetual, as well as existing investors, including Imperial Innovations and Lansdowne Partners.

"Completing this financing is a testament to the potential of Circassia's business, management and technology," said Steve Harris, Circassia's CEO. "We have made good progress advancing our anti-allergy products during the last year, and successfully completing this funding, particularly in the current challenging market conditions, is a strong vote of confidence from a syndicate of world-class investors."

Circassia, whose immune control technologies target allergies and organ rejection, completed an initial investment round of GBP6 million ($11.8 million) in January 2007. During the last year the company has finalised preparations to complete the phase II clinical testing programme for its lead product against cat dander allergy, and finalised the acquisition of its ToleroTrans organ anti-rejection technology. Following this second investment round, Circassia has increased its current cash balance to GBP15 million ($29.8 million), and plans to utilise the funds both to progress its clinical development programmes and to acquire additional technologies that fit its specialty business model.

Circassia's products have the potential to address significant market opportunities. Currently, over 150 million people suffer from allergic rhinitis in the US and Europe, and existing treatments either provide symptomatic relief only or require lengthy specialist physician supervision over a period of many months due to potential serious, even life-threatening, adverse reactions. In contrast, Circassia's technology uses small sections of the allergen molecules responsible for causing allergies (termed T-cell epitopes) to rapidly desensitize sufferers, while minimizing the potential for adverse reactions. The company's ToleroTrans technology uses a similar scientific approach designed to desensitize transplant patients and thereby reduce the risk of organ rejection.

About Circassia

Circassia is a specialty biopharmaceutical company focused on developing medicines designed to control immune system responses. The company has a highly experienced management team with a proven track record in product development and commercialisation, and having successfully completed two substantial fundraising rounds is backed by a syndicate of world-class venture capital and institutional investors.

Circassia's lead products target allergies utilising the company's proprietary T-cell epitope desensitization technology, which was originally developed at Imperial College London. The company is also developing its ToleroTrans organ anti-rejection technology, which uses a similar approach to down-regulate immune responses in transplant patients. Circassia has a number of ongoing development programmes, with the most advanced against cat dander allergy having successfully completed a phase II clinical trial.

For more information please visit http://www.circassia.co.uk.


'/>"/>
SOURCE Circassia Ltd
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Primera Biosystems Raises $21 Million in Series B Private Round
2. Cellectar, Inc. Raises $13 Million in Private Offering
3. Follica Raises $5.5 M To Advance New Treatment for Androgenetic Alopecia Into the Clinic
4. Anesiva Raises $45 Million in Common Stock Offering
5. Perrigo Announces Final FDA Approval of Dexcels OTC Omeprazole; Raises Full Year Earnings Guidance
6. Antibody Engineering Company f-star Raises EUR 3.0 Million in a Second Closing of its Series A Financing Round From Novo A/S
7. Gen-Probe Reports Strong Financial Results for Third Quarter 2007, Raises Full-Year Guidance for Earnings Per Share and Total Revenues
8. Thermo Fisher Scientific Reports Record Third Quarter Revenues and Adjusted EPS and Raises Full-Year Guidance
9. VisEn Medical Raises $7 Million in Series B Financing
10. MannKind Corporation Raises $250 Million in Self Managed Registered Direct Offerings of Common Stock
11. Cardiosolutions Raises $7 Million for Spacer Technology to Mitigate Mitral Regurgitation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... -- VMS BioMarketing, a leading provider of patient support solutions, has ... (CNE) network, which will launch this week. The VMS CNEs ... professionals to enhance the patient care experience by delivering peer-to-peer ... care professionals to help women who have been diagnosed and ... ...
(Date:10/11/2017)... , ... October 11, 2017 , ... Disappearing forests and ... lives of over 5.5 million people each year. Especially those living in larger cities ... Treepex - based in one of the most pollution-affected countries globally - decided to ...
(Date:10/11/2017)... ... October 11, 2017 , ... Singh Biotechnology ... drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer and Activator of Transcription ... is able to cross the cell membrane and bind intracellular STAT3 and inhibit ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights that give it exclusive ... a technology developed in collaboration with Children’s Hospital Los Angeles (CHLA). ...
Breaking Biology Technology:
(Date:4/17/2017)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... Annual Report on Form 10-K on Thursday April 13, 2017 with ... ... Relations section of the Company,s website at http://www.nxt-id.com  under "SEC ... . 2016 Year Highlights: Acquisition ...
(Date:4/13/2017)... 2017 According to a new market research report ... Identity Administration, and Authorization), Service, Authentication Type, Deployment Mode, Vertical, and Region ... expected to grow from USD 14.30 Billion in 2017 to USD 31.75 ... ... MarketsandMarkets Logo ...
(Date:4/11/2017)... -- Research and Markets has announced the addition of ... offering. ... market to grow at a CAGR of 30.37% during the period ... has been prepared based on an in-depth market analysis with inputs ... growth prospects over the coming years. The report also includes a ...
Breaking Biology News(10 mins):